Compare · MRNA vs SRRK
MRNA vs SRRK
Side-by-side comparison of Moderna Inc. (MRNA) and Scholar Rock Holding Corporation (SRRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and SRRK operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.89B, about 3.6x SRRK ($5.25B).
- Over the past year, MRNA is up 67.2% and SRRK is up 30.7% - MRNA leads by 36.6 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 10 for SRRK).
- MRNA has more recent analyst coverage (25 ratings vs 19 for SRRK).
- Company
- Moderna Inc.
- Scholar Rock Holding Corporation
- Price
- $47.04-1.19%
- $44.57+1.78%
- Market cap
- $18.89B
- $5.25B
- 1M return
- -13.42%
- -7.97%
- 1Y return
- +67.22%
- +30.67%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 15
- 10
- Recent ratings
- 25
- 19
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
Latest SRRK
- Director Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)
- Director Reed Joshua was granted 6,839 shares, increasing direct ownership by 43% to 22,571 units (SEC Form 4)
- Director Brudnick Richard was granted 6,839 shares, increasing direct ownership by 45% to 21,896 units (SEC Form 4)
- Director Burow Kristina was granted 6,839 shares, increasing direct ownership by 6% to 117,710 units (SEC Form 4)
- Director Gilman Michael was granted 6,839 shares, increasing direct ownership by 12% to 62,055 units (SEC Form 4)
- Director Peng Katie was granted 6,839 shares, increasing direct ownership by 21% to 39,747 units (SEC Form 4)
- Director Akkaraju Srinivas was granted 6,839 shares, increasing direct ownership by 32% to 27,971 units (SEC Form 4)
- Scholar Rock Holding Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference